Rep. Kevin Hern Unloads Biogen Inc. (NASDAQ:BIIB) Shares

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on August 18th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 8/18/2026.

Biogen Price Performance

Biogen stock opened at $222.67 on Thursday. Biogen Inc. has a 12-month low of $135.39 and a 12-month high of $225.59. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average price of $208.99 and a 200-day moving average price of $196.25. The firm has a market capitalization of $32.90 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.39 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 12.39 EPS for the current year.

Hedge Funds Weigh In On Biogen

Several institutional investors have recently bought and sold shares of the business. Range Advisory LLC purchased a new stake in shares of Biogen during the 2nd quarter worth $201,000. Corient Private Wealth LP increased its position in shares of Biogen by 14.7% during the second quarter. Corient Private Wealth LP now owns 42,397 shares of the biotechnology company’s stock worth $9,160,000 after purchasing an additional 5,445 shares in the last quarter. Amundi lifted its holdings in shares of Biogen by 91.8% during the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after purchasing an additional 726,004 shares during the last quarter. Groupe la Francaise acquired a new stake in shares of Biogen in the 2nd quarter worth $112,000. Finally, California State Teachers Retirement System grew its stake in Biogen by 21,439.6% during the 2nd quarter. California State Teachers Retirement System now owns 47,535,145 shares of the biotechnology company’s stock worth $10,270,443,000 after buying an additional 47,314,458 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BIIB shares. Wedbush increased their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a research report on Thursday, August 13th. HC Wainwright increased their target price on Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada lifted their target price on Biogen from $240.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Finally, Barclays boosted their target price on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $227.79.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI SC-AI, Eisai and Biogen’s once-weekly subcutaneous autoinjector for patients with mild cognitive impairment or mild Alzheimer’s disease dementia. The at-home treatment provides an alternative to biweekly hospital infusions, potentially improving patient adherence, reducing clinic visits and lowering healthcare-resource requirements. China represents a substantial long-term market, with an estimated 17 million people affected by early Alzheimer’s disease in 2024. Launch is planned during Eisai’s fiscal 2026. China approval of LEQEMBI SC-AI
• Positive Sentiment: Zorevunersen data supported pipeline optimism. Four-year follow-up in Dravet syndrome showed durable seizure reductions and sustained cognitive and behavioral improvements, with a generally well-tolerated safety profile. Completion of enrollment in the Phase 3 EMPEROR study adds a meaningful late-stage development milestone for Biogen’s partnered pipeline. Zorevunersen clinical data
• Positive Sentiment: Commercial sentiment around LEQEMBI improved after Canada’s drug agency issued a positive recommendation supporting public reimbursement for eligible early-Alzheimer’s patients. Recent analyst target increases also reinforced expectations for LEQEMBI uptake and Biogen’s transition toward newer growth assets. Canada LEQEMBI reimbursement recommendation
• Neutral Sentiment: Biogen completed its acquisition of RayThera to expand into small-molecule immunology therapies. The lead program has only recently entered Phase 1, so the deal offers strategic diversification but carries clinical, execution and financial risks before it can contribute material revenue. Biogen RayThera acquisition

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.